Staloral Allergen of birch pollen, drops 10 ml 5 pcs

The exact mechanism of allergen action during allergen-specific immunotherapy (ASIT) is not fully understood. The following biological changes have been proven:

• appearance of specific antibodies (IgG4) playing the role of “blocking antibodies”;
• reduction of specific IgE levels in plasma;
• reduction of reactivity of cells involved in the allergic reaction;
• increased interaction between Th2 and Th1, leading to positive changes in cytokine production (decreased IL-4 and increased g-interferon) that regulate IgE production.

The administration of ASIT also inhibits the development of both the early and late phase of the immediate allergic reaction.

Indications

Allergen specific immunotherapy (ASIT) for patients with allergic reaction type 1 (IgE mediated), suffering from rhinitis, conjunctivitis, mild or moderate form of seasonal bronchial asthma, and hypersensitivity to birch pollen.

Immunotherapy can be administered to adults and children from 5 years of age.

Pharmacological effect

The exact mechanism of action of the allergen during allergen-specific immunotherapy (ASIT) has not been fully studied. The following biological changes have been proven:

the appearance of specific antibodies (IgG4), which play the role of “blocking antibodies”;
decrease in the level of specific IgE in plasma;
decreased reactivity of cells involved in an allergic reaction;
increased activity of interaction between Th2 and Th1, leading to a positive change in the production of cytokines (decreased IL-4 and increased β-interferon), regulating the production of IgE.

Carrying out ASIT also inhibits the development of both the early and late phases of the immediate allergic reaction.

Active ingredient

Birch pollen allergen

Composition

sublingual drops

Active ingredient:

Allergen extract from birch pollen 10 IR/ml*, 300 IR/ml

Excipients:

sodium chloride,

glycerol,

mannitol,

purified water

* IR/ml – Reactivity Index – biological unit of standardization.

Contraindications

Hypersensitivity to one of the excipients (see list of excipients);
Autoimmune diseases, immune complex diseases, immunodeficiencies;
Malignant neoplasms;
Uncontrolled or severe bronchial asthma (forced expiratory volume <70%); Therapy with beta-blockers (including local therapy in ophthalmology); Severe inflammatory diseases of the oral mucosa, for example, erosive-ulcerative form of lichen planus, mycoses.

Side Effects

Carrying out ASIT can cause adverse reactions, both local and general.
The dosage and treatment regimen may be revised by the attending physician in case of an individual reaction or changes in the general condition of the patient.

Local reactions:

oral: itching in the mouth, swelling, discomfort in the mouth and throat, disruption of the salivary glands (increased salivation or dry mouth);
gastroenterological reactions: abdominal pain, nausea, diarrhea.

Usually these symptoms go away quickly, and there is no need to change the dosage or treatment regimen. If symptoms occur frequently, the possibility of continuing therapy should be reconsidered.

General reactions are rare:

rhinitis, conjunctivitis, asthma, urticaria require symptomatic treatment with H1-antagonists, beta-2 mimetics or corticosteroids (orally). The physician should reconsider the dosage and treatment regimen or the possibility of continuing ASIT.
in extremely rare cases, generalized urticaria, angioedema, laryngeal edema, severe asthma, anaphylactic shock are possible, which requires the abolition of ASIT.

Rare side effects not related to Ig-E mediator reactions:

asthenia, headache;
exacerbation of preclinical atopic eczema;
delayed reactions of the serum sickness type with arthralgia, myalgia, urticaria, nausea, adenopathy, fever, which requires the abolition of ASIT.

All side effects should be reported to your doctor.

Interaction

Do not use simultaneously with beta-blockers.

Possible simultaneous use with symptomatic antiallergic drugs (H1-antihistamines, beta-2 mimetics, corticoids, mast cell degranulation inhibitors) for better tolerability of ASIT.

Overdose

If the prescribed dose is exceeded, the risk of side effects increases, which requires symptomatic treatment.

Manufacturer

Stallergen, France